Fenebrutinib Drug Asset Due Diligence Report 2026

This Fenebrutinib Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 3

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Fenebrutinib can convert its Small molecule drug profile and BTK C481S biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Fenebrutinib (query alias: fenebrutinib)
Modality / target	Small molecule drug; BTK C481S; BTK C481S inhibitors
Highest global status	Phase 3
Originator	Genentech, Inc.
Active developers	Hoffmann-La Roche, Inc., F. Hoffmann-La Roche Ltd., Roche China Holding Ltd.

The MCP disease footprint includes Multiple Sclerosis, Multiple sclerosis relapse, Multiple Sclerosis, Primary Progressive. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
PACTR202212815145545	Phase 3	Recruiting	736	Not disclosed
NCT07161258	Phase 2	Recruiting	12	Plasma Concentration of Fenebrutinib
ISRCTN46432183	Phase 1	Ongoing	32	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

[Ad hoc announcement pursuant to Art. 53 LR] Roche's fenebrutinib confirms its potential as first and only BTK inhibitor for relapsing and primary progressive MS in third positive Phase III study (FENhance 1)

Phase 3; n=1497; evaluation: Positive. Reported fields: ARR(96 weeks): Difference (%) = -51 Met; ARR(96 weeks): Difference (%) = -51 Met

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study

Phase 3; n=985; evaluation: Positive. Reported fields: Time to onset of composite confirmed disability progression(24 weeks) = 24.0 % ; -

Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis

Phase 3; n=985; evaluation: Non-inferior. Reported fields: cCDP12(12-week) = The results showed that fenebrutinib was non-inferior compared to ocrelizumab, the only approved therapy in PPMS, as measured by a delay in the onset of composite confirmed disability progression over a period of at least 120 weeks of treatment. Met; cCDP12(12-week) = The results showed that fenebrutinib was non-inferior compared to ocrelizumab, the only approved therapy in PPMS, as measured by a delay in the onset of composite confirmed disability progression over a period of at least 120 weeks of treatment. Met

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Fenebrutinib addresses Multiple Sclerosis, Multiple sclerosis relapse, Multiple Sclerosis, Primary Progressive. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 39 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: BTK C481S records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-08	Roche and Nurix Therapeutics to partner in $2.3bn deal	Phase 3	US$2,300.0M stated total
2026-06-02	Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases	Phase 2	US$112.5M upfront; US$1,030.0M milestones
2026-05-14	Aptose, facing cash crunch, exits blood cancer pact after Hanmi buyout blocks development	Phase 1	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Crystal form of Fenebrutinib compound as well as preparation method and application of crystal form”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO